Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7094427 | IMPAX LABS INC | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May, 2022
(1 year, 11 months ago) | |
US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) |
Rytary is owned by Impax Labs Inc.
Rytary contains Carbidopa; Levodopa.
Rytary has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rytary are:
Rytary was authorised for market use on 07 January, 2015.
Rytary is available in capsule, extended release;oral dosage forms.
Rytary can be used as treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, method of providing a therapeutically effective and stable median blood plasma level of levodopa, treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease.
The generics of Rytary are possible to be released after 26 December, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jan 07, 2018 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment o...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL